Collections

Advancements of Immunotherapy in the Treatment of Urologic Cancer
Editor: Awais Ullah Ihsan

Submission Deadline: 17 May 2025 (Status: Open)

Special Issue Editor


Dr.Awais Ullah Ihsan      Email   |   Website
Institute of research and clinic Montreal (IRCM), Quebec, Canada
Interests: Immunotherapy, Urologic Cancer, Oncology, Inflammation, Molecular Biology, Animal models


Special Issue Information

Dear Colleagues,

Urologic cancers pose a lethal threat, so early treatment interventions are essential to combat their progression and improve patient outcomes. The rapid advancements in immunotherapy have revolutionized the treatment landscape for urologic cancers, offering promising avenues for the improvement of patient outcomes and quality of life. This special issue explores the latest advancements of immunotherapy in the genetics and treatment of urologic cancers, focuses on novel therapeutic approaches, clinical trials and future perspectives, and also highlights the underlying influences of immune checkpoint inhibitors, adoptive cell therapies and personalized immunotherapies on patient outcomes and quality of life. This issue utilizes the evolving landscape of combination therapies to probe into synergistic approaches that more effectively combat urologic cancers by dint of the immune system, and sheds light on the latest advancements of immunotherapy in the treatment of urologic cancers through comprehensive reviews, original research articles and insightful commentaries.

Topics:

This special issue explores various aspects of immunotherapy in the treatment of urologic cancers. Notably, it highlights the advancements in immunotherapy techniques tailored to urologic malignancies. Topics include, but are not limited to:

• Advancements of Immunotherapy in the Treatment of Urologic Cancer

• Immune Checkpoint Inhibitors

• Adoptive Cell Therapy

• Cancer Vaccines

• Combination Therapies

• Biomarkers and Predictive Factors

• Immune-Related Adverse Events

Expected outcomes

The special issue aims to provide a comprehensive understanding of the latest advancements of immunotherapy in the treatment of urologic cancers. This issue is dedicated to improving patient outcomes and quality of life through exploring novel therapeutic approaches, clinical trials and future perspectives, fostering collaboration and innovation in the ongoing fight against urologic cancers through in-depth reviews, original research articles and insightful commentaries, as well as enhancing patient care and outcomes in the realm of urologic cancer immunotherapy by deepening understanding, improving treatment strategies and inspiring future perspectives.

Awais Ullah Ihsan
Guest Editor


Keywords

Immunotherapy, Urologic Cancer, Immune Checkpoint Inhibitors, Adoptive Cell Therapies, Personalized Medicine, Clinical Trials, Patient Outcomes, Quality of Life, Future Perspectives


Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.aeurologia.com/journalx_aedu/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Journal
Publication year
Channels
Sort by Default Latest Most read